Last reviewed · How we verify
Antiplatelet treatment
At a glance
| Generic name | Antiplatelet treatment |
|---|---|
| Also known as | ASA, Clopidogrel, Ticagrelor and acetylsalicylic acid |
| Sponsor | University of Calgary |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Stroke Progression
Key clinical trials
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure (NA)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1, PHASE2)
- Comparing Two PFO Closure Devices in Adults With Previous Stroke or TIA (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiplatelet treatment CI brief — competitive landscape report
- Antiplatelet treatment updates RSS · CI watch RSS
- University of Calgary portfolio CI